Ticker

Dogwood  licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected to commence in the middle of 2026 at the University of Virginia ALPHARETTA, Ga., April 15, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX”, “Dogwood” or “the Company”), a company that focuses…

REGENXBIO (NASDAQ: RGNX - Get Free Report) and Dogwood Therapeutics (NASDAQ: DWTX - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership. Analyst Recommendations This is a summary of recent

Dogwood Therapeutics (NASDAQ: DWTX - Get Free Report) is projected to issue its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($1.22) per share for the quarter. Parties may visit the the company's upcoming Q4 2025 earning results page for the latest details on the

ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the fourth quarter and full year ended December 31, 2025.

Shares of Dogwood Therapeutics, Inc (NASDAQ: DWTX - Get Free Report) were up 1.7% during mid-day trading on Friday. The company traded as high as $3.17 and last traded at $3.06. Approximately 49,806 shares traded hands during trading, an increase of 47% from the average daily volume of 33,985 shares. The stock had previously closed